Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial

Matthew J. Ellis(Guardant (United States)), M. Borgs(Novartis (Switzerland))
Journal of Clinical Oncology
September 15, 2001
Cited by 1,062


Related Papers